Salem Capital Management Inc. Acquires 397 Shares of Eli Lilly And Co (LLY)

Salem Capital Management Inc. grew its position in shares of Eli Lilly And Co (NYSE:LLY) by 7.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,558 shares of the company’s stock after acquiring an additional 397 shares during the period. Salem Capital Management Inc.’s holdings in Eli Lilly And Co were worth $721,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Athena Capital Advisors LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter worth approximately $26,000. Wakefield Asset Management LLLP bought a new stake in Eli Lilly And Co during the 4th quarter valued at about $27,000. Trust Department MB Financial Bank N A lifted its holdings in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares in the last quarter. Larson Financial Group LLC purchased a new position in Eli Lilly And Co during the 4th quarter valued at about $29,000. Finally, Ironwood Financial llc purchased a new position in Eli Lilly And Co during the 4th quarter valued at about $30,000. 79.58% of the stock is owned by hedge funds and other institutional investors.

Shares of LLY opened at $119.96 on Wednesday. Eli Lilly And Co has a 12 month low of $77.09 and a 12 month high of $132.13. The firm has a market cap of $128.52 billion, a P/E ratio of 21.61, a P/E/G ratio of 2.35 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 EPS. On average, equities analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 136,577 shares of the company’s stock in a transaction dated Thursday, January 17th. The stock was sold at an average price of $118.33, for a total value of $16,161,156.41. Following the transaction, the insider now directly owns 117,866,748 shares of the company’s stock, valued at approximately $13,947,172,290.84. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,003,959 shares of company stock valued at $125,426,338. 0.11% of the stock is currently owned by company insiders.

Several analysts have weighed in on the stock. Barclays reissued a “buy” rating and set a $140.00 target price on shares of Eli Lilly And Co in a research report on Sunday. Guggenheim cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price objective for the company. in a research note on Thursday, April 11th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a research note on Wednesday, April 10th. Bank of America set a $129.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Finally, Credit Suisse Group set a $121.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $118.02.

ILLEGAL ACTIVITY NOTICE: “Salem Capital Management Inc. Acquires 397 Shares of Eli Lilly And Co (LLY)” was posted by PressOracle and is the sole property of of PressOracle. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://pressoracle.com/news/2019/04/17/salem-capital-management-inc-acquires-397-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is dollar cost averaging (DCA)?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.